Q-omics provides the consensus-scored GATA1 profile across patient tissues and cancer cell-line models. GATA1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GATA1 is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, GATA1 RNA expression shows 14,595 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, LUAD, and THYM as cancer lineages where GATA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GATA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GATA1 survival associations across molecular data types. GATA1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GATA1 RNA expression–survival associations across cancer types. High GATA1 expression shows unfavorable associations in UCEC and BLCA, but favorable associations in HNSC, COAD, ACC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for GATA1 RNA expression.
This table summarizes GATA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GATA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GATA1 shows lower tumor expression in LUAD, LUSC, BLCA, UCEC and KICH and higher tumor expression in KIRC. The LUAD box plot shows higher GATA1 RNA expression in normal versus tumor tissue (log2 FC = −0.913, t-test p < 0.001).
This table shows molecular features associated with GATA1 in patient tissues and cancer cell lines. In patient samples, GATA1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GATA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SKIN.
